Real-world immunotherapy for newly diagnosed multiple myeloma
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how well first-line immunotherapy works for people newly diagnosed with multiple myeloma in real-world clinical settings in China. The goal is to understand what treatments are used and how patients respond.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with multiple myeloma.
- You plan to start your first cancer treatment with immunotherapy at the hospital where this study is being done.
- Your first treatment includes a proteasome inhibitor (like bortezomib), an immunomodulatory drug (like lenalidomide), or an anti-CD38 antibody (like daratumumab), alone or together with other medicines.
- You are 18 years old or older.
- You are able to understand the study and agree to take part by signing a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment called RN1201, which uses a patient's own immune cells to fight multiple myeloma that has high-risk genetic features. The goal is to see if this therapy can help control the disease better after initial treatment.
This trial tests a new drug called RN1201 as a first-line treatment for multiple myeloma, a blood cancer. The study aims to see if it is safe and effective for patients who have never been treated for this condition before.
This study compares a new investigational drug (AZD0120) with a standard stem cell transplant for people with newly diagnosed multiple myeloma who have already completed initial treatment. The goal is to see if the new drug works as well as or better than the transplant in keeping the cancer from coming back.
This study uses a special imaging test called a PET scan to learn more about multiple myeloma and how it responds to treatment. The results may help doctors better predict outcomes and tailor care for people with newly diagnosed disease.
This trial tests a new experimental drug called CM336 for people with multiple myeloma that has come back or stopped responding to standard treatments. The drug may work by helping your immune system attack and destroy myeloma cells. If you join, you will receive the study treatment and be closely monitored to see how well it works and how safe it is.
This study tests an investigational drug for people with multiple myeloma, a type of blood cancer. It aims to see how safe and effective the treatment is for patients who are newly diagnosed or have relapsed after prior therapy.
Hear when a new Newly Diagnosed Multiple Myeloma (NDMM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.